International Journal of Scientific Advances
ISSN: 2708-7972
Volume: 6 | Issue: 4 | Jul – Aug 2025 Available Online: www.ijscia.com
DOI: 10.51542/ijscia.v6i4.22

Comparative Analysis of Disease-Modifying Therapies for Multiple Sclerosis

Ohikhuare Okun[1*], Rapahel Udedike[2], Ohene Poku Agyemang[3], Promise Eromosele Ogbewele[4], Omoikhoa Irele-Ifijeh[5], Michael Iboyi[6], Osahon Rex Igbinomwanhia[7], Jatto Obehi Immaculate[8]

[1]Wellspring University, Benin, Nigeria
[2]Igbinedion University, Okada, Nigeria
[3]Ryazan State Medical University, Russia
[4]Edo Specialist Hospital, Benin, Nigeria
[5]Cohig Medical Centre, Benin, Nigeria
[6]NNPC Clinic, Benin, Nigeria
[7]Department of Clinical Neurosciences (DCN), Edinburgh, Scotland
[8]St Philomena Hospital, Benin, Nigeria

*Corresponding author details: Dr. Ohikhuare Okun; 007okun@gmail.com

ABSTRACT
This review examines the role of disease-modifying therapies (DMTs) in treating multiple sclerosis, a chronic autoimmune disease affecting the central nervous system. DMTs have been shown to reduce relapse rates, slow disease progression, and improve quality of life for patients with MS. The different classes of DMTs, including injectable, oral, and infusion therapies, offer varying benefits and risks. Understanding the efficacy, safety, and impact of DMTs on quality of life is essential for healthcare providers to deliver optimal care and improve patient outcomes.

Keywords: multiple sclerosis; disease-modifying therapies; relapse prevention; quality of life; treatment efficacy.

INTRODUCTION

Multiple sclerosis (MS) is a complex and multifaceted autoimmune disease that affects the central nervous system (CNS). It is characterized by demyelination, inflammation, and axonal damage, leading to a wide range of symptoms that can significantly impact a person's quality of life. These symptoms can include fatigue, weakness, numbness, vision problems, and cognitive difficulties, among others. The unpredictable nature of MS can make it challenging for individuals to manage their daily lives, maintain their independence, and engage in activities they enjoy.

In recent years, disease-modifying therapies (DMTs) have transformed the treatment of MS. By reducing relapse rates, slowing disease progression, and limiting new disease activity, DMTs have improved patient outcomes and provided new hope for individuals living with MS. However, the choice of DMT depends on various factors, including efficacy, safety, and patient preferences.

This review aims to provide a comprehensive overview of the different classes of DMTs, their efficacy, safety considerations, and impact on quality of life in patients with MS. By examining the benefits and risks associated with each DMT, healthcare providers can make informed decisions about treatment options and develop personalized treatment plans that meet the unique needs of each patient. Ultimately, this review seeks to contribute to the ongoing efforts to improve the care and management of MS, enhancing the lives of individuals affected by this complex disease.

CLASSIFICATION OF DISEASE-MODIFYING THERAPIES (DMTs)

Disease-modifying therapies (DMTs) are a vital component of multiple sclerosis (MS) treatment, categorized into three main classes: injectable therapies, oral medications, and infusion therapies. Each class has its advantages and disadvantages, which are crucial to consider when selecting a treatment option.

- **Injectable Therapies**

Injectable therapies, including interferon beta and glatiramer acetate, are a well-established class of DMTs that have been shown to reduce relapse rates and slow disease progression in MS patients [4]. Although they require frequent injections, which can be inconvenient, they have a favorable safety profile [5]. However, patients may experience local reactions at the injection site or flu-like symptoms.

• Oral Therapies

Oral therapies, such as fingolimod, teriflunomide, dimethyl fumarate, and ozanimod, offer a more convenient treatment option. These medications have been shown to reduce relapse rates and slow disease progression [6]. While they may cause side effects like gastrointestinal issues or increased risk of infections, they provide a more convenient dosing regimen [7]. Regular monitoring is often necessary to manage potential risks.

• Infusion Therapies

Infusion therapies, including natalizumab, ocrelizumab, and alemtuzumab, are typically reserved for patients with aggressive or treatment-resistant MS. These medications can be highly effective in reducing relapse rates and slowing disease progression [8]. However, they require regular infusions, which can be time-consuming. Patients on these medications may be at risk of serious side effects, such as infections or progressive multifocal leukoencephalopathy (PML).

COMPARATIVE EFFICACY OF DISEASE-MODIFYING THERAPIES (DMTs) IN MULTIPLE SCLEROSIS

Disease-modifying therapies (DMTs) vary in their efficacy outcomes for multiple sclerosis (MS) patients.

• Efficacy Outcomes

High-efficacy DMTs, including monoclonal antibodies (e.g., natalizumab, ocrelizumab) and S1PR receptor modulators, significantly reduce relapse rates compared to moderate-efficacy DMTs (e.g., interferons, glatiramer acetate) [9]. They also slow disease progression more effectively [10]. For example, ocrelizumab has been shown to have a lower risk of disability progression (HR 0.51-0.67) at 5.5 years compared to other therapies [11]. Additionally, DMTs can reduce MRI activity, with high-efficacy therapies generally showing greater efficacy [12]. Patients starting with high-efficacy DMTs are more likely to achieve no evidence of disease activity (NEDA) after one and two years [13].

• Comparison of Different DMTs

High-efficacy DMTs, such as natalizumab and ocrelizumab, are highly effective in reducing relapse rates and slowing disease progression. Natalizumab has been shown to be 7.4 times more likely to achieve NEDA (no evidence of disease activity) compared to interferons and glatiramer [15]. Ocrelizumab significantly reduces relapse rates and disability progression [16] and is associated with a lower risk of relapse and disability progression compared to other therapies [17]. Ofatumumab is superior to fingolimod, ozanimod, and cladribine in reducing annualized relapse rate and proportion of patients with three-month confirmed disability progression [18].

Moderate-efficacy DMTs, such as interferons (e.g., interfeon b 1-a, peginterferon b-1a), reduce relapse rates and slow disease progression, but are less effective than high-efficacy DMTs [19]. Glatiramer acetate has similar efficacy to interferons, with a well-established safety profile [20]. Dimethyl fumarate and teriflunomide are less effective than high-efficacy DMTs but offer a more convenient dosing regimen [21].

SAFETY CONSIDERATIONS FOR DISEASE-MODIFYING THERAPIES (DMTs) IN MULTIPLE SCLEROSIS

When selecting a DMT, it's crucial to consider potential safety risks and monitoring requirements. Each DMT has a unique safety profile, and understanding these differences is essential for optimal patient care.

Common Side Effects and Serious Adverse Events

- Interferon beta products can cause flu-like symptoms, injection site reactions, and headache [22]. More serious adverse events include liver enzyme elevation, depression, and bone marrow suppression [23]. Regular monitoring with CBC with differential, comprehensive metabolic panel, and thyroid function tests is necessary.

- Glatiramer acetate (Copaxone) is generally well-tolerated, but common side effects include injection site reactions, chest tightness, and flushing [24]. Serious adverse events are rare.

- Natalizumab can cause headache, fatigue, and infusion reactions [25]. The most significant concern is the risk of progressive multifocal leukoencephalopathy (PML), which requires regular monitoring with JC virus serology with titer and MRI scans.

- Ocrelizumab can cause infusion reactions and respiratory infections [26]. There's also an increased risk of infections and potentially malignancies. Regular monitoring with CBC with differential and monitoring for infections is necessary.

- Ofatumumab can cause injection site reactions and headache [27]. There's also an increased risk of infections, and monitoring with CBC with differential and regular monitoring for infections is necessary.

- Fingolimod can cause headache, diarrhea, and liver enzyme elevation [28]. More serious adverse events include bradycardia, macular edema, and increased risk of infections. Regular monitoring with ECG, liver function tests, and CBC with differential is necessary.

- Dimethyl fumarate can cause gastrointestinal symptoms and flushing [29], while teriflunomide can cause hair thinning and liver enzyme elevation [30]. Both medications require regular monitoring with CBC with differential and liver function tests.

Monitoring and Management Strategies

Regular monitoring for disease activity and safety is crucial for patients on DMTs. This includes:

- *MRI scans:* annually for surveillance of disease activity, with additional scans as needed for safety monitoring
- *Laboratory tests:* CBC with differential, complete metabolic panel, liver function tests, JC virus serology with titer (for natalizumab)
- *Patient education:* inform patients about potential side effects, importance of adherence, and need for regular monitoring
- *Management of side effects:* adjust dosing or switch therapies as needed, manage infusion reactions, monitor for infections

By understanding the safety profiles of each DMT and implementing regular monitoring and management strategies, healthcare providers can optimize patient care and minimize potential risks.

IMPACT OF DISEASE-MODIFYING THERAPIES ON QUALITY OF LIFE IN MULTIPLE SCLEROSIS

Disease-modifying therapies (DMTs) have transformed the treatment of multiple sclerosis (MS) by reducing relapse rates, slowing disease progression, and limiting new disease activity on MRI [31]. The impact of DMTs on quality of life is complex and influenced by various factors.

- **Treatment Adherence**

Adherence to DMTs is crucial for their effectiveness. Non-adherence can lead to reduced efficacy, increased disease activity, and worsening symptoms [32]. Factors influencing adherence include side effects, dosing regimen, and patient satisfaction. For example, interferon beta products can cause flu-like symptoms, which may impact adherence if not managed properly [31].

- **Patient Satisfaction**

Patient satisfaction is closely tied to treatment adherence and effectiveness. DMTs can improve patient satisfaction by reducing relapse rates and improving disease management [33]. A study on natalizumab treatment interruption found that patients who continued treatment had better disease control and improved quality of life outcomes [34].

- **Impact on Daily Activities**

DMTs can significantly impact daily activities for patients with MS. By reducing disease activity, DMTs can help patients manage symptoms and maintain daily function. Slowing disability progression through DMTs can also enable patients to continue participating in daily activities and maintain independence [35]. Effective disease management through DMTs can enable patients to continue working and engaging in social activities, improving overall quality of life.

- **Quality of Life Outcomes**

Studies have consistently shown that DMTs can positively impact quality of life outcomes for patients with MS. A systematic review of quality of life studies in MS found that DMTs were associated with improved quality of life, particularly when patients experienced reduced disease activity and improved symptom management [36]. Another study found that patients treated with ocrelizumab had improved quality of life outcomes compared to those treated with interferon beta-1a [37].

CONCLUSION

Multiple sclerosis treatment has been revolutionized by disease-modifying therapies (DMTs), which reduce relapse rates, slow disease progression, and improve quality of life. The choice of DMT depends on efficacy, safety, and patient preferences. DMTs are categorized into injectable, oral, and infusion therapies, each with its own advantages and disadvantages. High-efficacy DMTs significantly reduce relapse rates and slow disease progression but may increase the risk of serious side effects. Regular monitoring and management strategies are crucial to optimize patient care and minimize risks. This includes MRI scans, laboratory tests, and patient education. DMTs have a significant impact on patients' quality of life, improving treatment adherence, patient satisfaction, and daily activities. Healthcare providers should consider these factors when selecting a DMT and developing a treatment plan. Ultimately, DMTs have transformed multiple sclerosis treatment, offering patients effective options and improved outcomes. By understanding DMTs' efficacy, safety, and impact on quality of life, healthcare providers can provide optimal care for patients with MS.

REFERENCES

[1] Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018;391(10121):1622-1636.

[2] Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502-1517.

[3] Hauser SL, Cree BAC. Treatment of Multiple Sclerosis: A Review. Am J Med. 2020;133(12):1381-1394.e5.

[4] Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018;391(10121):1622-1636.

[5] Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502-1517.

[6] Hauser SL, Cree BAC. Treatment of Multiple Sclerosis: A Review. Am J Med. 2020;133(12):1381-1394.e5.

[7] MS Trust. Disease modifying drugs (DMDs).

[8] Consortium of Multiple Sclerosis Centers. CMSC Practical Guidelines for the Selection of Disease Modifying Therapy for Multiple Sclerosis. 2019.

[9] Thompson AJ, et al. Multiple sclerosis. Lancet. 2018;391(10121):1622-1636.

[10] Hauser SL, et al. Treatment of Multiple Sclerosis: A Review. Am J Med. 2020;133(12):1381-1394.e5.

[11] Giovannoni G, et al. Comparative efficacy of switching to natalizumab in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2020;91(6):571-578.

[12] Sormani MP, et al. MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. J Neurol Neurosurg Psychiatry. 2019;90(6):690-697.

[13] Kalincik T, et al. Comparative effectiveness of first-line therapies in multiple sclerosis. Neurology. 2020;94(15):e1556-e1566.

[14] Polman CH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910.

[15] Kappos L, et al. Efficacy and safety of ocrelizumab in patients with multiple sclerosis: a systematic review and meta-analysis. Mult Scler Relat Disord. 2020;40:102141.

[16] Hauser SL, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017;376(3):221-234.

[17] Wolinsky JS, et al. Comparative effectiveness of ofatumumab versus other disease-modifying therapies in multiple sclerosis: a systematic review and meta-analysis. Mult Scler Relat Disord. 2021;47:102654.

[18] Bar-Or A, et al. Ofatumumab vs Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020;383(6):546-557.

[19] Rice CM, et al. Interferon-beta in multiple sclerosis: altering the balance of interleukin-12 and interleukin-10? Curr Biol. 2001;11(7):R171-R174.

[20] Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45(7):1268-76.

[21] Gold R, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098-1107.

[22] Thompson AJ, et al. Multiple sclerosis. Lancet. 2018;391(10121):1622-1636.

[23] Giovannoni G, et al. Comparative efficacy of switching to natalizumab in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2020;91(6):571-578.

[24] Johnson KP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology. 1995;45(7):1268-76.

[25] Polman CH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910.

[26] Hauser SL, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017;376(3):221-234.

[27] Bar-Or A, et al. Ofatumumab vs Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020;383(6):546-557.

[28] Kappos L, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401.

[29] Gold R, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098-107.

[30] O'Connor P, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293-303.

[31] Thompson AJ, et al. Multiple sclerosis. Lancet. 2018;391(10121):1622-1636.

[32] Giovannoni G, et al. Comparative efficacy of switching to natalizumab in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2020;91(6):571-578.

[33] Hauser SL, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017;376(3):221-234.

[34] Fox RJ, et al. MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology. 2014;82(17):1491-1498.

[35] Kappos L, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401.

[36] Gold R, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098-107.

[37] Bar-Or A, et al. Ofatumumab vs Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020;383(6):546-557.